相似文献
1
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Circulation. 2012 Jan 24;125(3):e291; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.056077.
2
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Circulation. 2012 Jan 24;125(3):e290; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.053710.
3
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Circulation. 2012 Jan 24;125(3):e292; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.057422.
4
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
5
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
Circulation. 2013 Mar 19;127(11):e504. doi: 10.1161/CIRCULATIONAHA.112.133041.
6
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.
7
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.
8
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.
9
Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
Nat Rev Nephrol. 2015 Jan;11(1):3. doi: 10.1038/nrneph.2014.221. Epub 2014 Nov 25.
10
Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):131-2. doi: 10.1038/nrgastro.2015.7. Epub 2015 Jan 20.
Zotero 插件